James L. Reading

James L. Reading

Auto-generated profile, based on publicly available information

James L. Reading

Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in Cell
Verified
Journal Article
Open access
KLKevin Litchfield
Kevin Litchfield
JRJames L. Reading
James L. Reading
CPClare Puttick
Clare Puttick
KTKrupa Thakkar
Krupa Thakkar
CAChris Abbosh
Chris Abbosh
CSCharles Swanton
Charles Swanton
Checkpoint inhibitors (CPIs) augment adaptive immunity. Systematic pan-tumor analyses may reveal the relative importance of tumor-cell-intrinsic and microenvironmental features underpinning CPI sensitization. Here, we collated whole-exome and transcriptomic data for >1,000 CPI-treated patients across seven tumor types, utilizing standardized bioinformatics workflows and clinical outcome criteria to validate multivariable predictors of CPI sensitization. Clonal tumor mutation burden (TMB) was the strongest predictor of CPI response, followed by total TMB and CXCL9 expression. Subclonal TMB, somatic copy alteration burden, and histocompatibility leukocyte antigen (HLA) evolutionary divergence failed to attain pan-cancer significance. Dinucleotide variants were identified as a source of immunogenic epitopes associated with radical amino acid substitutions and enhanced peptide hydrophobicity/immunogenicity. Copy-number analysis revealed two additional determinants of CPI outcome supported by prior functional evidence: 9q34 (TRAF2) loss associated with response and CCND1 amplification associated with resistance. Finally, single-cell RNA sequencing (RNA-seq) of clonal neoantigen-reactive CD8 tumor-infiltrating lymphocytes (TILs), combined with bulk RNA-seq analysis of CPI-responding tumors, identified CCR5 and CXCL13 as T-cell-intrinsic markers of CPI sensitivity.

1 August 2017 in The Lancet Oncology
Verified
Journal Article
Open access
STSamra Turajlic
Samra Turajlic
KLKevin Litchfield
Kevin Litchfield
HXHang Xu
Hang Xu
RRRachel Rosenthal
Rachel Rosenthal
NMNicholas McGranahan
Nicholas McGranahan
CSCharles Swanton
Charles Swanton
The focus of tumour-specific antigen analyses has been on single nucleotide variants (SNVs), with the contribution of small insertions and deletions (indels) less well characterised. We investigated whether the frameshift nature of indel mutations, which create novel open reading frames and a large quantity of mutagenic peptides highly distinct from self, might contribute to the immunogenic phenotype. We analysed whole-exome sequencing data from 5777 solid tumours, spanning 19 cancer types from The Cancer Genome Atlas. We compared the proportion and number of indels across the cohort, with a subset of results replicated in two independent datasets. We assessed in-silico tumour-specific neoantigen predictions by mutation type with pan-cancer analysis, together with RNAseq profiling in renal clear cell carcinoma cases (n=392), to compare immune gene expression across patient subgroups. Associations between indel burden and treatment response were assessed across four checkpoint inhibitor datasets. We observed renal cell carcinomas to have the highest proportion (0·12) and number of indel mutations across the pan-cancer cohort (p<2·2 × 10-16), more than double the median proportion of indel mutations in all other cancer types examined. Analysis of tumour-specific neoantigens showed that enrichment of indel mutations for high-affinity binders was three times that of non-synonymous SNV mutations. Furthermore, neoantigens derived from indel mutations were nine times enriched for mutant specific binding, as compared with non-synonymous SNV derived neoantigens. Immune gene expression analysis in the renal clear cell carcinoma cohort showed that the presence of mutant-specific neoantigens was associated with upregulation of antigen presentation genes, which correlated (r=0·78) with T-cell activation as measured by CD8-positive expression. Finally, analysis of checkpoint inhibitor response data revealed frameshift indel count to be significantly associated with checkpoint inhibitor response across three separate melanoma cohorts (p=4·7 × 10-4). Renal cell carcinomas have the highest pan-cancer proportion and number of indel mutations. Evidence suggests indels are a highly immunogenic mutational class, which can trigger an increased abundance of neoantigens and greater mutant-binding specificity. Cancer Research UK, UK National Institute for Health Research (NIHR) at the Royal Marsden Hospital National Health Service Foundation Trust, Institute of Cancer Research and University College London Hospitals Biomedical Research Centres, the UK Medical Research Council, the Rosetrees Trust, Novo Nordisk Foundation, the Prostate Cancer Foundation, the Breast Cancer Research Foundation, the European Research Council.

20 March 2019 in Nature
Verified
Journal Article
Closed access
PDF file
TCThe TRACERx consortium
The TRACERx consortium
RRRachel Rosenthal
Rachel Rosenthal
ECElizabeth Larose Cadieux
Elizabeth Larose Cadieux
RSRoberto Salgado
Roberto Salgado
MBMaise Al Bakir
Maise Al Bakir
CSCharles Swanton
Charles Swanton

4 October 2019 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
TCTRACERx consortium
TRACERx consortium
KJKroopa Joshi
Kroopa Joshi
MMMarc Robert de Massy
Marc Robert de Massy
MIMazlina Ismail
Mazlina Ismail
JRJames L. Reading
James L. Reading
BCBenny Chain
Benny Chain

12 April 2024 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
KEKatey S. S. Enfield
Katey S. S. Enfield
ECEmma Colliver
Emma Colliver
CLClaudia S Y. Lee
Claudia S Y. Lee
AMAlastair Magness
Alastair Magness
DMDavid A. Moore
David A. Moore
MAMihaela Angelova
Mihaela Angelova
Understanding the role of the tumor microenvironment (TME) in lung cancer is critical to improving patient outcomes. We identified four histology-independent archetype TMEs in treatment-naïve early-stage lung cancer using imaging mass cytometry in the TRACERx study (n = 81 patients/198 samples/2.3 million cells). In immune-hot adenocarcinomas, spatial niches of T cells and macrophages increased with clonal neoantigen burden, whereas such an increase was observed for niches of plasma and B cells in immune-excluded squamous cell carcinomas (LUSC). Immune-low TMEs were associated with fibroblast barriers to immune infiltration. The fourth archetype, characterized by sparse lymphocytes and high tumor-associated neutrophil (TAN) infiltration, had tumor cells spatially separated from vasculature and exhibited low spatial intratumor heterogeneity. TAN-high LUSC had frequent PIK3CA mutations. TAN-high tumors harbored recently expanded and metastasis-seeding subclones and had a shorter disease-free survival independent of stage. These findings delineate genomic, immune, and physical barriers to immune surveillance and implicate neutrophil-rich TMEs in metastasis. Significance: This study provides novel insights into the spatial organization of the lung cancer TME in the context of tumor immunogenicity, tumor heterogeneity, and cancer evolution. Pairing the tumor evolutionary history with the spatially resolved TME suggests mechanistic hypotheses for tumor progression and metastasis with implications for patient outcome and treatment. This article is featured in Selected Articles from This Issue, p. 897

17 April 2018 in Immunological Reviews
Verified
Journal Article
Closed access
PDF file
JRJames L. Reading
James L. Reading
FGFelipe Gálvez‐Cancino
Felipe Gálvez‐Cancino
CSCharles Swanton
Charles Swanton
ALAlvaro Lladser
Alvaro Lladser
KPKarl S. Peggs
Karl S. Peggs
SQSergio A. Quezada
Sergio A. Quezada